Welcome to our dedicated page for Telix Pharmaceuticals ADR SEC filings (Ticker: TLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telix Pharmaceuticals Limited (TLX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including Form 20-F and a series of Form 6-K reports. As a foreign private issuer listed on the Nasdaq Global Select Market, Telix uses Form 6-K to furnish key announcements originally released on the Australian Securities Exchange (ASX) to U.S. investors.
Through these filings, readers can review clinical, regulatory, and financial updates that Telix has formally submitted to the U.S. Securities and Exchange Commission. Examples referenced in recent 6-Ks include press releases on CMS granting Transitional Pass-Through status for Gozellix, revenue and operational updates, regulatory correspondence for TLX250-CDx, and clinical trial milestones such as progress in the ProstACT Global study. Each 6-K typically attaches the underlying ASX announcement as an exhibit, preserving the full text for detailed analysis.
For investors evaluating Telix’s radiopharmaceutical portfolio, SEC filings complement ASX disclosures by providing an official record of developments in products like Illuccix, Gozellix, TLX101-CDx, TLX250-CDx, and therapeutic candidates in oncology and rare diseases. Annual reports on Form 20-F, referenced in company legal notices, contain broader information on risk factors, business description, and financial statements.
On Stock Titan, these filings are paired with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand the significance of new 6-K submissions, annual reports, and other disclosures. Investors can use this page to monitor Telix’s ongoing reporting obligations, track how clinical and regulatory events are reflected in official filings, and review the company’s historical SEC record, including exhibits related to clinical trials, reimbursement decisions, and capital markets activity.
Telix Pharmaceuticals Limited filed a Form 6-K highlighting two key updates first released on the Australian Securities Exchange. The company reports that the Chinese National Medical Products Administration has accepted a New Drug Application for Illucix, marking an important regulatory step for this product in China. Telix also states that it achieved its FY 2025 guidance with US$804 million (A$1.2 billion) in revenue and is accelerating growth with the launch of Gozellix. Together, these disclosures point to strong recent commercial performance and progress in expanding the company’s product portfolio and geographic reach.
Telix Pharmaceuticals Limited submitted a foreign issuer report to the U.S. securities regulator to furnish investors with a copy of a presentation given at the JP Morgan Healthcare Conference 2026. The company states that it filed an announcement with the Australian Securities Exchange on January 12, 2026 titled “Telix JP Morgan Healthcare Conference 2026 Presentation,” and has attached this as an exhibit for U.S. investors. This filing is primarily administrative, making the same information available in the U.S. market that was released in Australia.
Telix Pharmaceuticals Limited submitted a Form 6-K to update U.S. investors on a clinical development milestone first disclosed in Australia. On December 8, 2025, the company filed an announcement with the Australian Securities Exchange titled “1st Patient Dosed in ProstACT Global Randomized Tx Expansion,” and this announcement is attached to the Form 6-K as Exhibit 99.1. The filing itself mainly serves as a cross-border notice and does not include additional financial results or transaction details beyond referencing the attached announcement.
Telix Pharmaceuticals Limited reported that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted transitional pass-through status for Gozellix. The company filed an announcement with the Australian Securities Exchange titled "CMS Grants Transitional Pass-Through Status for Gozellix," and the related press release is attached as Exhibit 99.1 to the report. No financial metrics, guidance, or additional transaction details are included in the filing.
Telix Pharmaceuticals Limited submitted a Form 6-K summarizing two announcements it filed with the Australian Securities Exchange in August 2025. One announcement, dated August 28, 2025, provides a regulatory update on its TLX250-CDx program. The other, dated August 5, 2025, presents historical financials in U.S. dollars and unaudited operating expenses for the first half of 2025. Both announcements are attached as exhibits to the Form 6-K.
Telix Pharmaceuticals Limited (TLX) has furnished a Form 6-K announcing its Q2 2025 top-line result. The company disclosed US$240 million in quarterly revenue, a 63% year-over-year increase, via an accompanying ASX press release (Exhibit 99.1). No additional income-statement, cash-flow or forward-guidance metrics are included in this filing. The document serves primarily to place the Australian announcement into the U.S. market via the SEC.
While the strong revenue growth signals continuing commercial traction for Telix’s radiopharmaceutical portfolio, investors will need to consult the full press release or upcoming results for margin, profit and outlook details. The filing was signed by Company Secretary Genevieve Ryan on 22 July 2025.
FAQ
What is the current stock price of Telix Pharmaceuticals ADR (TLX)?
What is the market cap of Telix Pharmaceuticals ADR (TLX)?
